Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

11 treatments under study, led by Fludarabine

Research Leaders

5 sponsors active, led by Hackensack Meridian Health

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Phase 1 (1)
Phase 2 (2)

Trial Status

Completed1
Recruiting1
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT07214688Phase 2RecruitingPrimary

Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

NCT04220684Phase 1CompletedPrimary

Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML

NCT04127721Phase 2WithdrawnPrimary

Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation

Showing all 3 trials

Research Network

Common Treatments

  • Fludarabine3
  • Tacrolimus2
  • Membranebound Interleukin21expanded Haploidentical Natural Killer Cells1
  • Busulfan1
  • Posttransplant Cyclophosphamide Ptcy1

Active Sponsors

  • Hackensack Meridian Health1
  • Kiadis Pharma1
  • M.D. Anderson Cancer Center1
  • National Cancer Institute (NCI)1
  • Sumithira Vasu1

Top Investigators

Related Conditions

  • Refractory Acute Myeloid Leukemia1
  • Hematologic And Lymphocytic Disorder1
  • Blasts 10 Percent Or More Of Bone Marrow Nucleated Cells1
  • Hematopoietic And Lymphoid Cell Neoplasm1
  • Recurrent Acute Myeloid Leukemia1

Activity Timeline